Teriparatide Does Not Exacerbate Bone Metastases in Breast Cancer Bone Metastasis Model.

BACKGROUND/AIM: Breast cancer frequently metastasizes to bone, and chemotherapy and hormone therapy can increase osteoporosis risk. Teriparatide (TPTD), an osteoporosis treatment that promotes bone formation, is contraindicated in patients with bone metastases due to concerns about osteosarcoma in animal studies. However, its effects on metastatic bone tumors remain unclear. This study aimed to evaluate TPTD's effects on breast cancer bone metastases using a mouse model.

MATERIALS AND

METHODS

C57BL/6 mice were injected with E0771 breast cancer cells to establish bone metastasis and breast cancer models. Mice were assigned to the vehicle-treated group (control) or to the TPTD-treated group (80 μg/kg, subcutaneously three times weekly). Tumor weight, volume, bone destruction, pathological fractures, distant metastasis, tumor proliferation (Ki-67, BrdU), and bone microstructure were assessed at 4 and 6 weeks.

RESULTS

In both models, no significant differences in tumor weight or volume were observed between the TPTD and control groups. In the bone metastasis model, bone destruction and pathological fractures were not significantly different. No distant metastasis was observed and there were no significant differences in the percentages of Ki-67-positive and BrdU-positive cells in both models. In the bone microstructure analysis at 6 weeks post-injection, bone volume/tissue volume and trabecular thickness increased in the bone metastasis model in the TPTD group (p=0.02 and p<0.01, respectively), and trabecular separation decreased in the TPTD group (p=0.01).

CONCLUSION

TPTD did not cause tumor growth, pathological fractures, or bone destruction in our in vivo models, indicating that it may be safe for use in breast cancer.